Tom Malefyt has significant pharmaceutical industry experience in manufacturing, pre-formulation evaluation, formulation, analysis, documentation, and registration of new drugs. Prior to joining Synosia, Tom led a pharmaceutical start-up effort to evaluate and refine a cell-specific drug delivery technology and an antigen-specific T-cell modulation technology from the University of Kansas. Since first joining the pharmaceutical industry at SmithKline and French Laboratories in 1984, Tom has acquired experience in managing the chemistry, manufacturing and controls (CMC) development of both early-phase and late-phase drug candidates, in both large and small pharmaceutical companies. Tom joined Syntex Research (later Roche) in 1988, where he held positions of increasing leadership and responsibility. He has developed traditional small molecule, peptide, recombinant vaccine and protein drug candidates. Tom earned his doctorate in chemistry at the University of California, Santa Barbara, and gained further experience with postdoctoral fellowships at the University of Queensland (enzymology), and the University of Kansas (pharmaceutical chemistry).